Novavax, Inc. (NVAX)

Market Cap	1.58B +25.1%
Revenue (ttm)	1.12B +64.7%
Net Income	440.30M
EPS	2.58
Shares Out	162.94M
PE Ratio	3.77
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,300,954
Open	9.64
Previous Close	9.62
Day's Range	9.44 - 10.00
52-Week Range	5.01 - 11.97
Beta	2.63
Analysts	Hold
Price Target	11.33 (+16.56%)
Earnings Date	May 7, 2026

About NVAX

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 5, 1995
• Employees: 749
• Stock Exchange: NASDAQ
• Ticker Symbol: NVAX
• Website: https://www.novavax.com

Analyst Summary

According to 9 analysts, the average rating for NVAX stock is "Hold." The 12-month stock price target is $11.33, which is an increase of 16.56% from the latest price.

Price Target

$11.33

(16.56% upside)

Analyst Consensus: Hold